In vitro neutralization of prions with PrP^Sc-specific antibodies

REFERENCES

• Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216:136-44; PMID:6801762; http://dx.doi.org/10.1126/science.6801762
   PubMed Web of Science ®Google Scholar
• Aguzzi A, Sigurdson C, Heikenwaelder M. Molecular mechanisms of prion pathogenesis. Annu Rev Pathol 2008; 3:11-40; PMID:18233951; http://dx.doi.org/10.1146/annurev.pathmechdis.3.121806.154326
   PubMed Web of Science ®Google Scholar
• Geshwind MD. Clinical trials for prion disease: difficult challenges but hope for the future. Lancet Neurol (2009) 8:304-6.
   PubMed Web of Science ®Google Scholar
• Haley NJ, Hoover EA. Chronic Wasting Disease of Cervids: Current Knowledge and Future Perspectives. Annu Rev Anim Biosci 2014; 3:205–325; PMID:25387112
   PubMed Web of Science ®Google Scholar
• Sigurdsson EM, Brown DR, Daniels M, Kascsak RJ, Kascsak R, Carp R, Meeker HC, Frangione B, Wisniewski T. Immunization delays the onset of prion disease in mice. Am J Pathol 2002; 161:13-7; PMID:12107084; http://dx.doi.org/10.1016/S0002-9440(10)64151-X
   PubMed Web of Science ®Google Scholar
• Hanan E, Goren O, Eshkenazy M, Solomon B. Immunomodulation of the human prion peptide 106–126 aggregation. Biochem Biophys Res Commun 2001; 280:115-20; PMID:11162487; http://dx.doi.org/10.1006/bbrc.2000.4097
   PubMed Web of Science ®Google Scholar
• Koller MF, Grau T, Christen P. Induction of antibodies against murine full-length prion protein in wild-type mice. J Neuroimmunol 2002; 132:113-6; PMID:12417440; http://dx.doi.org/10.1016/S0165-5728(02)00316-8
   PubMed Web of Science ®Google Scholar
• Rosset MB, Ballerini C, Grégoire S, Metharom P, Carnaud C, Aucouturier P. Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotide-CpG in mice. J Immunol 2004; 172:5168-74; PMID:15100253; http://dx.doi.org/10.4049/jimmunol.172.9.5168
   PubMed Web of Science ®Google Scholar
• Polymenidou M, Heppner FL, Pellicioli EC, Urich E, Miele G, Braun N, Wopfner F, Schätzl HM, Becher B, Aguzzi A. Humoral immune response to native eukaryotic prion protein correlates with antiprion protection. Proc Natl Acad Sci U S A 2004; 101(Suppl 2):14670-6; PMID:15292505; http://dx.doi.org/10.1073/pnas.0404772101
   PubMed Web of Science ®Google Scholar
• Schwarz A, Krätke O, Burwinkel M, Riemer C, Schultz J, Henklein P, Bamme T, Baier M. Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci Lett 2003; 350:187-9; PMID:14550926; http://dx.doi.org/10.1016/S0304-3940(03)00907-8
   PubMed Web of Science ®Google Scholar
• Gilch S, Schätzl HM. Promising developments bringing prion diseases closer to therapy and prophylaxis. Trends Mol Med 2003; 9:367-9; PMID:13129701; http://dx.doi.org/10.1016/S1471-4914(03)00144-8
   PubMed Web of Science ®Google Scholar
• Goni F, Mathiason CK, Yim L, Wong K, Hayes-Klug J, Nalls A, Peyser D, Estevez V, Denkers N, Xu J, et al. Mucosal immunization with an attenuated Salmonella vaccine partially protects white-tailed deer from chronic wasting disease. Vaccine (2015) 33:726-33; PMID:25539804; http://dx.doi.org/10.1016/j.vaccine.2014.11.035
   PubMed Web of Science ®Google Scholar
• Cashman NR, Loertscher R, Nalbantoglu J, Shaw I, Kascsak RJ, Bolton DC, Bendheim PE. Cellular isoform of scrapie agent protein participates in lymphocyte activation. Cell (1990) 61:185-192; PMID:1969332; http://dx.doi.org/10.1016/0092-8674(90)90225-4
   PubMed Web of Science ®Google Scholar
• Huang L, Su X, Federoff HJ. Single-Chain Fragment Variable Passive Immunotherapies of Neurodegenerative diseases. Int. J. Mol. Sci. (2013) 14:19109-27; PMID:24048248; http://dx.doi.org/10.3390/ijms140919109
   PubMed Web of Science ®Google Scholar
• Solforosi L, Criado JR, McGavern DB, Wirz S, Sánchez-Alavez M, Sugama S, DeGiorgio LA, Volpe BT, Wiseman E, Abalos G, et al. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 2004; 303:1514-6; PMID:14752167; http://dx.doi.org/10.1126/science.1094273
   PubMed Web of Science ®Google Scholar
• Sonati T, Reimann R, Falsig J, Baral P, O'Connor T, Hornemann S, Yaganoglu S, Li B, Herrmann U, Wieland B, et al. The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein. Nature (2013) 501;102-6; PMID:23903654; http://dx.doi.org/10.1038/nature12402
   PubMed Web of Science ®Google Scholar
• Marciniuk K, Maattanen P, Taschuk R, Airey D, Potter A, Cashman N, Griebel P, Napper S. Development of a Multivalent, PrPSc-Specific Prion Vaccine through Rational Optimization of Three Disease-Specific Epitopes. Vaccine (2014) 32:1988-97; PMID:24486363; http://dx.doi.org/10.1016/j.vaccine.2014.01.027
   PubMed Web of Science ®Google Scholar
• Paramithiotis E, Pinard M, Lawton T, LaBoissiere S, Leathers VL, Zou W-Q, Estey LA, Lamontagne J, Lehto MT, Kondejewski LH, et al. A prion protein epitope selective for the pathologically misfolded conformation. Nat Med 2003; 9:893-9; PMID:12778138; http://dx.doi.org/10.1038/nm883
   PubMed Web of Science ®Google Scholar
• Guest W, Cashman N, Plotkin S. Structure-Based Prediction of Unstable Regions in Proteins: Applications to Protein Misfolding Diseases. Bull Am Phys Soc 2009; 54. Available at http://meetings.aps.org/link/BAPS.2009.MAR.A40.13
   Google Scholar
• Gossert AD, Bonjour S, Lysek DA, Fiorito F, Wüthrich K. Prion protein NMR structures of elk and of mouse/elk hybrids. Proc Natl Acad Sci U S A 2005; 102:646-50; PMID:15647363; http://dx.doi.org/10.1073/pnas.0409008102
   PubMed Web of Science ®Google Scholar
• Soto C. Constraining the loop, releasing prion infectivity. Proc Natl Acad Sci U S A 2009; 106:10-1; PMID:19118191; http://dx.doi.org/10.1073/pnas.0811625106
   PubMed Web of Science ®Google Scholar
• Taschuk R, Marciniuk K, Maaattanen P, Madampage C, Hedlin P, Potter A, Lee J, Cashman N, Griebel P, Napper S. Safety, Specificity and Immunogenicity of a PrPSc-specific prion vaccine based on the YYR Disease-Specific Epitope. Prion Feb (2014) 7;8(1):51-9.
   PubMed Web of Science ®Google Scholar
• Hedlin PD, Cashman NR, Li L, Gupta J, Babiuk LA, Potter AA, Griebel P, Napper S. Design and Delivery of a cryptic (PrPC epitope for induction of PrP(Sc)-specific antibody responses. Vaccine (2009) 28:981-8; PMID:19925901; http://dx.doi.org/10.1016/j.vaccine.2009.10.134
   PubMed Web of Science ®Google Scholar
• Van der Merwe J, Aiken J, Westaway D, McKenzie D. The Standard Scrapie Cell Assay: Development, Utility and Prospects. Viruses, (2015) 7: 180-98; PMID:25602372; http://dx.doi.org/10.3390/v7010180
   PubMed Web of Science ®Google Scholar
• Maattanen P, Taschuk R, Ross L, Marciniuk K, Bertram L, Potter A, Cashman N, Napper S. PrPSc-specific antibodies do not induce prion disease or misfolding of PrPC in highly susceptible Tga20 mice. Prion. (2013) 5:434-9; http://dx.doi.org/10.4161/pri.26639
   Web of Science ®Google Scholar
• Bueler H, A Aguzzi, A Sailer, RA Greiner, P Autenried, M Aguet, C Weissmann. Mice devoid of PrP are resistant to scrapie. Cell 1993 73:1339-47; PMID:8100741; http://dx.doi.org/10.1016/0092-8674(93)90360-3
   PubMed Web of Science ®Google Scholar
• Feraudet C, Morel N, Simon S, Volland H, Frobert Y, Creminon C, Vilette D, Lehmann S, Grassi J. Screening of 145 Anti-PrP Monoclonal Antibodies for Their Capacity to Inhibit PrPSc Replication in Infected Cells. J Biol Chem (2005) 280: 11247-58; PMID:15618225; http://dx.doi.org/10.1074/jbc.M407006200
   PubMed Web of Science ®Google Scholar
• Liu H-N, Tjostheim S, Dasilva K, Taylor D, Zhao B, Rakhit R, et al. Targeting of monomer/misfolded SOD1 as a therapeutic strategy for amyotrophic lateral sclerosis. J Neurosci (2012) 32: 8791-9; PMID:22745481; http://dx.doi.org/10.1523/JNEUROSCI.5053-11.2012
   PubMed Web of Science ®Google Scholar
• Li L, Napper S, Cashman N. Immunotherapy for prion diseases: opportunities and obstacles. Immunotherapy (2010) 2:269-82; PMID:20635933; http://dx.doi.org/10.2217/imt.10.3
   PubMed Web of Science ®Google Scholar
• Hanan E, Priola S, Solomon B. Antiaggregating Antibody Raised Against Human PrP 106–126 Recognizes Pathological and Normal Isoforms of the Whole Prion Protein. Cell Molec Neurbiol (2001) 21: 693-703; http://dx.doi.org/10.1023/A:1015199904354
   PubMed Web of Science ®Google Scholar
• Pankiewicz J, Prelli F, Sy M, Kascsak R, Kascsak R, Spinner D, Carp R, Meeker H, Sadowski M, Wisniewski T. Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur J Neurosci 23: 2635-47; PMID:16817866; http://dx.doi.org/10.1111/j.1460-9568.2006.04805.x
   PubMed Web of Science ®Google Scholar
• Sadowski M, Pankiewicz J, Prelli F, Scholtzova H, Spinner D, Kascsak RB, Kascsak RJ, Wisniewski T. Anti-PrP Mab 6D11 suppresses PrPSc replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo. Neurobiol Dis. 34: 267-78; PMID:19385058; http://dx.doi.org/10.1016/j.nbd.2009.01.013
   PubMed Web of Science ®Google Scholar